Skip to main content

Table 1 Demographic and clinical characteristics of IgAN patients, disease controls, and healthy controls

From: TWEAK/Fn14 system and crescent formation in IgA nephropathy

Characteristics IgAN LN MN FSGS MCD Healthy controls P value
( n  = 116) ( n  = 18) ( n  = 12) ( n =  8) ( n =  12) ( n  = 50)
Age (years) 34.0 ± 10.9 33.0 ± 9.9 55.7 ± 9.5 A-E 35.9 ± 13.1 31.8 ± 19.3 33.6 ± 5.5 <0.001
Men, n (%) 53 (45.7) 2 (11.1) 9 (75.0) 5 (62.5) 6 (50.0) 32 (64.0) 0.002
BMI (kg/m2) 21.7 ± 3.0 21.7 ± 4.5 23.5 ± 2.5 24.3 ± 5.3 23.3 ± 3.8 22.0 ± 2.0 0.08
Mean arterial pressure (mmHg) 83.8 ± 13.8 82.4 ± 16.3 87.3 ± 8.9 85.8 ± 10.1 79.1 ± 8.1 86.0 ± 11.0 0.62
eGFR (ml/min per 1.73 m2) 81.9 ± 29.0 82.8 ± 32.6 79.3 ± 29.4 76.8 ± 28.3 95.7 ± 23.7 N/A 0.56
CKD Stages 1/2/3/4/5 (KDOQI) (%)a 32/47/20/1/0 44/39/11/0/6 25/50/25/0/0 38/50/0/13/0 50/42/8/0/0 - 0.13
Urinary protein excretion (g/gCr) 0.61 ± 0.88 2.22 ± 2.62 F 3.76 ± 2.97 G 1.70 ± 1.91 5.46 ± 4.35 H,I,J N/A <0.001
uTWEAK (pg/mgCr, median, IQR) 94.3 (65.1, 147.1)K 130.8 (70.2, 163.8)L 151.9 (98.8, 285.1)M 168.9 (107.8, 304.7)N 180.6 (92.8, 331.8)O 64.2 (32.2, 84.9) <0.001
  1. Abbreviations: BMI, body mass index; eGFR, estimated glomerular filtration rate; uTWEAK, urinary TWEAK; IQR, interquartile range; IgAN, IgA nephropathy; LN, lupus nephritis; MN, membranous nephropathy; FSGS, focal segmental glomerulosclerosis; MCD, minimal change disease; NA, not available; ANOVA, analysis of variance; HSD, honest significant difference.
  2. aCKD stage 1, 2, 3, 4, and 5 were divided by eGFR ≥90, 60–89, 30–59, 15–29, and <15, respectively.
  3. Data are expressed as proportions, mean ± SD, or median (interquartile range [IQR]) as appropriate. Differences among the groups were analyzed by a one-way ANOVA. The multiple comparisons for age, BMI, mean arterial pressure, eGFR, and urinary protein excretion were performed by Tukey’s HSD mean separation tests. A nonparametric Steel-Dwass test was used for uTWEAK. Differences between the disease groups in gender and CKD stages were determined by χ2 tests. A: P < 0.001 vs. IgAN; B: P < 0.001 vs. LN; C: P < 0.001 vs. FSGS; D: P < 0.001 vs. MCD; E: P < 0.001 vs. healthy controls; F: P = 0.001 vs. IgAN; G: P < 0.001 vs. IgAN; H: P < 0.001 vs. IgAN; I: P < 0.001 vs. LN; J: P < 0.001 vs. FSGS; K: P < 0.001 vs. healthy controls; L: P = 0.001 vs. healthy controls; M: P < 0.001 vs. healthy controls; N: P = 0.005 vs. healthy controls; O: P = 0.001 vs. healthy controls.